Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data

Figure 4 Disease-free survival analysis in patients with early-stage hepatocellular carcinoma with or without copy number aberrations involving six important genes identified using OncoScan data. A: Patients with stage I/II hepatocellular carcinoma (HCC) (n = 120) and copy number aberrations (CNAs) involving critical genes (dashed line) exhibited worse outcome compared to those without the predictive gene-containing CNAs (solid line) (P = 0.0036). B: Patients with early-stage HCC with three or more CNAs affecting these six identified genes had worse outcome (≥ 3 CNAs affecting these genes, dashed line, n = 14 vs < 3 CNAs affecting these genes, solid line, n = 106; P < 0.0001). C: Patients with stage I HCC (n = 72) and CNAs affecting any of the six identified genes (MYC, WRN, ELAC2, GAK, SYK, or MECOM) were associated with worse outcome after resection (dashed line, P = 0.0209). D: Patients with stage II HCC (n = 48) with/without any of the CNAs affecting these six genes (MYC, WRN, ELAC2, GAK, SYK, or ) showed no difference in DFS (P = 0.15). DFS: Disease-free survival.